Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

This study compares a new antibody-drug conjugate called IBI354 — which delivers chemotherapy directly into cancer cells — against standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer whose disease has continued to grow during or after platinum-based chemotherapy (called platinum-resistant). **You may be eligible if...** - You are a woman aged 18 or older - You have been diagnosed with locally advanced or metastatic ovarian, fallopian tube, or primary peritoneal cancer (confirmed by biopsy) - Your cancer has progressed during or after your most recent treatment - You have at least one measurable tumor on imaging - Your heart function and blood counts are within acceptable ranges - Your expected survival is at least 12 weeks **You may NOT be eligible if...** - Your cancer is not classified as platinum-resistant - You have had more than the permitted number of prior treatments - You have serious heart, lung, or liver problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.